Stay current with the science and policy shaping biotech. Sign up for our biotech newsletter.
Good morning. We have a busy news day, highlighting significant oncology updates.
Key biotech news this morning
Sellas immunotherapy reduces AML mortality risk
Sellas Life Sciences’ experimental therapy lowered the risk of death by 41% versus standard care for patients with advanced acute myeloid leukemia, the company announced.
Also Read
- Neanderthal-Inherited DNA Segment Linked to Lower Schizophrenia Risk
- White House Withdraws FDA Commissioner Nomination of Heidi Overton
- Faulty Natural Killer Cells, Not Macrophages, Drive Rare Immune Disease, Study Finds
- Science Review Explores Cognitive Effects of GLP-1 Drugs Amid Mixed Alzheimer’s Trial Results


